BioCentury
ARTICLE | Clinical News

AST-120: Phase IIb started

May 4, 2009 7:00 AM UTC

Ocera began the double-blind, placebo-controlled, U.S. Phase IIb ASTUTE trial to evaluate 2 or 4 g of oral AST-120 given three times daily for 8 weeks in up to 150 patients. Ocera licensed AST-120 fro...